ArticleThe oncologist2026
OncoEducate: a pilot study of generative AI to enhance patient-clinician communication in genitourinary cancer care.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-driven precision diagnosis and treatment of prostate cancer: a narrative review.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OncoEducate is a clinician-supervised generative artificial intelligence (AI) application designed to deliver standardized, regimen-level, plain-language education at the point of care. We developed a templated handout generator using a locked prompt and predefined content structure that incorporates diagnosis, treatment regimen, and treatment intent, with clinician review prior to patient distribution. We then conducted a prospective, two-phase pilot at a single academic cancer center. In Phase I, six clinicians evaluated AI-generated handouts for nine commonly used palliative-intent genitourinary (GU) oncology regimens using 7-point Likert-scale items. In Phase II, patients with advanced kidney, prostate, or urothelial cancers initiating palliative-intent therapy received clinician-reviewed handouts and completed follow-up surveys at the next office or infusion visit or by telephone when in-person completion was not feasible. Clinicians rated handouts as useful (median 6/7) and accessible (median 6.5/7), with median accuracy ratings of 6-7/7 across domains. During an 8-week period, 20 of 21 approached patients enrolled (95%). Patients rated handouts as informative and readable (median 7/7 for both), and 65% correctly identified treatment intent as palliative. These findings support the feasibility and acceptability of clinician-reviewed, templated AI-generated handouts in routine GU oncology care, justifying larger randomized studies to evaluate clinical impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.